Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 3
2015 3
2016 3
2017 4
2018 3
2019 4
2020 3
2021 5
2022 7
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Cipriani A, et al. Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21. Lancet. 2018. PMID: 29477251 Free PMC article. Review.
In head-to-head studies, agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine, and vortioxetine were more effective than other antidepressants (range of ORs 1.19-1.96), whereas fluoxetine, fluvoxamine, reboxetine, and trazodone were the least effi …
In head-to-head studies, agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine, and vortioxetine were more e …
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N. Kishi T, et al. Mol Psychiatry. 2023 Jan;28(1):402-409. doi: 10.1038/s41380-022-01824-z. Epub 2022 Oct 17. Mol Psychiatry. 2023. PMID: 36253442 Free PMC article.
Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. In conclusion, desvenlafaxine, paroxetine, venlafaxine, and vortioxetine …
Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine …
Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis.
Oliva V, Lippi M, Paci R, Del Fabro L, Delvecchio G, Brambilla P, De Ronchi D, Fanelli G, Serretti A. Oliva V, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110266. doi: 10.1016/j.pnpbp.2021.110266. Epub 2021 Feb 5. Prog Neuropsychopharmacol Biol Psychiatry. 2021. PMID: 33549697
., agomelatine, bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, mirtazapine, paroxetine, reboxetine, sertraline, venlafaxine, and vortioxetine) and report data on treatment-emergent gastrointestinal SEs (i.e. nause …
., agomelatine, bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, mirtazapine, paro …
Comparative Remission Rates and Tolerability of Drugs for Generalised Anxiety Disorder: A Systematic Review and Network Meta-analysis of Double-Blind Randomized Controlled Trials.
Kong W, Deng H, Wan J, Zhou Y, Zhou Y, Song B, Wang X. Kong W, et al. Front Pharmacol. 2020 Nov 11;11:580858. doi: 10.3389/fphar.2020.580858. eCollection 2020. Front Pharmacol. 2020. PMID: 33343351 Free PMC article. Review.
For remission rate, agomelatine (OR 2.70, 95% CI 1.74-4.19), duloxetine (OR 1.88, 95% CI 1.47-2.40), escitalopram (OR 2.03, 95% CI 1.48-2.78), paroxetine (OR 1.74, 95% CI 1.25-2.42), quetiapine (OR 1.88, 95% CI 1.39-2.55), and venlafaxine (OR 2.28, 95% CI 1.69-3.07) were superior …
For remission rate, agomelatine (OR 2.70, 95% CI 1.74-4.19), duloxetine (OR 1.88, 95% CI 1.47-2.40), escitalopram (OR 2.03, 95% CI 1.48-2.78 …
Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis.
Li Z, Liu S, Wu Q, Li J, Yang Q, Wang X, Peng P, Wang Q, Liu Y, Li M, Hao Y, Xu H, He L, Wang Y, Chen S, Liu T. Li Z, et al. Int J Neuropsychopharmacol. 2023 Jun 23;26(6):373-384. doi: 10.1093/ijnp/pyad018. Int J Neuropsychopharmacol. 2023. PMID: 37105713 Free PMC article.
This study aims to evaluate the effectiveness, tolerability, and safety of vortioxetine in treating MDD based on real-world data. METHODS: A systematic search of 8 electronic databases was performed from inception until October 2022 to identify real-world studies, excludin …
This study aims to evaluate the effectiveness, tolerability, and safety of vortioxetine in treating MDD based on real-world data. MET …
Cognitive effects of vortioxetine in older adults: a systematic review.
Bishop MM, Fixen DR, Linnebur SA, Pearson SM. Bishop MM, et al. Ther Adv Psychopharmacol. 2021 Jul 22;11:20451253211026796. doi: 10.1177/20451253211026796. eCollection 2021. Ther Adv Psychopharmacol. 2021. PMID: 35186260 Free PMC article. Review.
While this systematic review demonstrated promising procognitive effects from vortioxetine, the included studies did not enroll older adults, who are at the highest risk of cognitive impairment. Therefore, our systematic review sought to investigate the effects of vorti …
While this systematic review demonstrated promising procognitive effects from vortioxetine, the included studies did not enroll older …
Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults.
Zhang X, Cai Y, Hu X, Lu CY, Nie X, Shi L. Zhang X, et al. Front Psychiatry. 2022 Jun 24;13:922648. doi: 10.3389/fpsyt.2022.922648. eCollection 2022. Front Psychiatry. 2022. PMID: 35815048 Free PMC article.
OBJECTIVE: We aimed to compare the efficacy, acceptability, and tolerability of vortioxetine in the treatment of Major Depressive Disorder (MDD) in adults. ...CONCLUSIONS: Vortioxetine is more advantageous over placebo in treating MDD among adults, but no significan …
OBJECTIVE: We aimed to compare the efficacy, acceptability, and tolerability of vortioxetine in the treatment of Major Depressive Dis …
New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE, McKenzie JE, Bailey AP, Sharma V, Moller CI, Badcock PB, Cox GR, Merry SN, Meader N. Hetrick SE, et al. Cochrane Database Syst Rev. 2021 May 24;5(5):CD013674. doi: 10.1002/14651858.CD013674.pub2. Cochrane Database Syst Rev. 2021. PMID: 34029378 Free PMC article.
Most antidepressants may be associated with a "small and unimportant" reduction in depression symptoms on the CDRS-R scale (range 17 to 113) compared with placebo (high certainty evidence: paroxetine: MD -1.43, 95% CI -3.90, 1.04; vilazodone: MD -0.84, 95% CI -3.03, 1.35; desvenl …
Most antidepressants may be associated with a "small and unimportant" reduction in depression symptoms on the CDRS-R scale (range 17 to 113) …
Antidepressants and Vertebral and Hip Risk Fracture: An Updated Systematic Review and Meta-Analysis.
de Filippis R, Mercurio M, Spina G, De Fazio P, Segura-Garcia C, Familiari F, Gasparini G, Galasso O. de Filippis R, et al. Healthcare (Basel). 2022 Apr 26;10(5):803. doi: 10.3390/healthcare10050803. Healthcare (Basel). 2022. PMID: 35627940 Free PMC article. Review.
No data were found among the most recent categories of antidepressants, such as vortioxetine and esketamine. All included studies reported hip fractures, while three of them also included vertebral fractures. ...
No data were found among the most recent categories of antidepressants, such as vortioxetine and esketamine. All included studies rep …
Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Huang IC, Chang TS, Chen C, Sung JY. Huang IC, et al. Int J Neuropsychopharmacol. 2022 Dec 12;25(12):969-978. doi: 10.1093/ijnp/pyac054. Int J Neuropsychopharmacol. 2022. PMID: 35981958 Free PMC article.
We conducted a meta-analysis to explore whether the cognitive function of patients with major depressive disorder (MDD) treated with vortioxetine would improve. METHODS: We systematically reviewed randomized controlled trials (RCTs) in the PubMed, Embase, and Cochrane data …
We conducted a meta-analysis to explore whether the cognitive function of patients with major depressive disorder (MDD) treated with vort …
39 results